63 results
424B3
QTTB
Q32 Bio Inc.
29 Apr 24
Prospectus supplement
5:10pm
of assets, strategic partnerships or other transactions. Based on the financing environment and the anticipated clinical development timeline for its
8-K
EX-99.5
QTTB
Q32 Bio Inc.
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
a similar term, in a similar economic environment. The Company determines the incremental borrowing rate at lease commencement, generally using
424B3
QTTB
Q32 Bio Inc.
13 Mar 24
Prospectus supplement
1:36pm
, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management … or other transactions. Based on the financing environment and the anticipated clinical development timeline for our lead program, HMI-103, we stopped
424B3
pn914ehlp5 17
14 Feb 24
Prospectus supplement
4:10pm
S-4/A
gfj9 ywkpi5zf3bvy
29 Jan 24
Registration of securities issued in business combination transactions (amended)
12:00am
8-K
EX-99.1
9xxcz3nmph3zx o0rx
26 Jan 24
Regulation FD Disclosure
4:13pm
425
droxi 92grnztgk
26 Jan 24
Business combination disclosure
12:00am
S-4
EX-2.1
8175g2i1ve ryidikr
15 Dec 23
Registration of securities issued in business combination transactions
7:15pm
S-4
81r72
15 Dec 23
Registration of securities issued in business combination transactions
7:15pm
S-4
EX-10.36
5qia85 biuzrhtzrez
15 Dec 23
Registration of securities issued in business combination transactions
7:15pm
425
o0tpj1
16 Nov 23
Business combination disclosure
4:19pm
425
gmlcf9p3uzfzug03tap3
16 Nov 23
Business combination disclosure
7:46am
8-K
EX-2.1
ia3v9s
16 Nov 23
Entry into a Material Definitive Agreement
7:45am
425
mlyp3twkgx2r7cyhzj6
16 Nov 23
Business combination disclosure
7:17am
8-K
EX-99.2
df3ny23fk20g
16 Nov 23
Q32 Bio and Homology Medicines Announce Merger Agreement
7:16am